We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

By HospiMedica International staff writers
Posted on 30 May 2024

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests. More...

The study, conducted by researchers at Flinders University (Bedford Park, Australia), evaluated the effectiveness of on-site pathology testing, or Point-of-Care Testing (POCT), specifically for detecting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in over 100 remote Aboriginal and Torres Strait Islander communities across Australia. In these areas, point-of-care testing is crucial for reaching patients who are otherwise isolated due to geographic, social, and cultural barriers. This is particularly vital given the high rates of infectious diseases like COVID-19 among the Aboriginal and Torres Strait Islander populations, where POCT offers cost-effective, accessible, and immediate diagnostic solutions.

The study focused on the analytical quality of the Aboriginal and Torres Strait Islander COVID-19 Point-of-Care (POC) Testing Program, initiated in April 2020. This program aimed to enhance the availability of rapid, molecular-based SARS-CoV-2 detection in remote communities. Extending to 105 communities, the program effectively helped prevent a significant number of COVID-19 cases, thereby saving considerable costs for the healthcare system. The quality of COVID-19 testing within the program was supported through comprehensive operator training and the implementation of a customized External Quality Assessment (EQA) program. This EQA program was developed in collaboration with the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP).

“Our study demonstrates that when point-of-care testing models are effectively established and managed, the quality of pathology results can be equivalent to laboratory tests, and the benefits for patients are overwhelmingly evident,” said Dr Susan Matthews from the International Centre for Point-of-Care Testing at Flinders University. “The COVID-19 program has now been expanded to include testing for Influenza A and B, and respiratory syncytial virus (RSV), as well as SARS-CoV-2 and has the potential to stem acute and infectious diseases in rural and remote areas whilst saving the government billions of dollars in health costs.” The study's findings were published in the journal Diagnostics on May 26, 2024.

Related Links:
Flinders University


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Syringe Pump
SP50 Series
New
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The nasal spray is created using the ‘Nano-in-Micron’ technology platform. The micron-sized powder is inhaled and travels along the nose-to-brain pathway, bypassing the blood-brain barrier to deliver the drug directly to the brain (Photo courtesy of The University of Hong Kong

New Nasal Spray Enables Prehospital Neuroprotection in Ischemic Stroke

Ischemic stroke, caused by arterial occlusion in the brain, requires time‑critical intervention to limit neuronal loss. Many patients arrive outside the narrow window for thrombolysis or thrombectomy,... Read more

Surgical Techniques

view channel
Image: MUSA-3 is designed to assist surgeons during open super‑microsurgical procedures by downscaling and stabilizing hand movements (Photo courtesy of Microsure)

Robotic Microsurgery System Gains CE Mark for Clinical Use in Europe

Microsure (Eindhoven, The Netherlands) announced on May 7, 2026 that its MUSA-3 system received CE mark approval, enabling clinical use in Europe. The milestone marks the company’s transition from product... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.